Filing Analysis
Stereotaxis, Inc. filed an 8-K to announce the release of its financial results for the second quarter of 2026. The filing serves as a formal notice that earnings data is being made public via an accompanying press release.
📋 Key Facts
- Report date: August 11, 2026
- Reporting period: Second Quarter of 2026
- The company issued an Earnings Press Release as Exhibit 99.1
- Signed by Kimberly R. Peery, Chief Financial Officer
Stereotaxis, Inc. has completed the acquisition of Robocath, a French société par actions simplifiée, representing 100% of its share capital and voting power. The company is incorporating supplemental risk factors related to this transaction via an S-3 registration statement.
🚩 Red Flags
- Significant integration risk: The company explicitly notes uncertainties regarding the ability to successfully integrate Robocath’s operations.
- Contingent payments: Potential for unexpected costs or charges related to contingent payments triggered by regulatory or commercial milestones.
- Revenue uncertainty: Revenue from purchase orders may be subject to contingencies outside of the Company's control.
📋 Key Facts
- Acquisition completed on July 7, 2026.
- Transaction involves 100% of the share capital and voting power of Robocath.
- The acquisition was governed by a Share Sale Agreement dated April 14, 2026.
- Includes a Joinder Agreement involving European Investment Bank and Supernova Invest.
- Company filed a Form S-3 on July 15, 2026, to facilitate the transaction/registration.
Stereotaxis, Inc. has completed the acquisition of 100% of Robocath, a French company, for approximately $20 million in cash and equity. The transaction involves significant issuance of common stock and pre-funded warrants to securityholders.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 4.5 million warrants and additional earnout shares.
- Potential for future dilutive impact from the required resale registration statement.
📋 Key Facts
- Completed acquisition of 100% of the share capital and voting power of Robocath on July 7, 2026.
- Issued 1,469,485 shares of common stock as part of the transaction.
- Issued 'pre-funded' warrants to purchase 4,575,143 shares of common stock at par value ($0.001).
- Issued 225,000 shares of common stock to Robocath’s financial advisor as a success fee.
- Potential earnout consideration up to $25.0 million in aggregate based on performance targets.
- The company must file a resale registration statement for the stock consideration issued.
Stereotaxis, Inc. reported the results of its Annual Meeting of Shareholders held on May 14, 2026, where shareholders voted on director elections, auditor ratification, and executive compensation.
📋 Key Facts
- The Annual Meeting was held on May 14, 2026, with 65.34% of the total voting power represented.
- Three Class I directors, David Benfer, Dr. Arun Menawat, and Dr. Myriam Curet, were elected to serve until the 2029 Annual Meeting.
- Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 with 79,036,638 votes in favor.
- Executive compensation was approved on a non-binding advisory basis with 52,143,334 votes in favor.
- Total outstanding voting power included 97,477,538 shares of common stock and 23,705,445 votes from Series A Convertible Preferred Stock.
Stereotaxis, Inc. reported its financial results for the first quarter ended March 31, 2026. The filing is a routine disclosure of quarterly performance and does not contain any immediate material changes to corporate structure or operations.
📋 Key Facts
- The company issued its Q1 2026 earnings press release on May 12, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The filing includes Exhibit 99.1, which contains the full earnings press release.
- The report was signed by Kimberly R. Peery, Chief Financial Officer.
Stereotaxis (STXS) entered into a Share Sale Agreement to acquire 100% of Robocath, a French robotic medical technology company, for $20 million upfront and up to $25 million in performance-based earnouts. The transaction is contingent upon Stereotaxis completing a debt restructuring with its lenders and obtaining French regulatory clearance.
🚩 Red Flags
- The acquisition is contingent on Stereotaxis completing a debt restructuring, indicating potential balance sheet stress.
- Stereotaxis is providing interim financing to the target before the deal closes, assuming operational risk for Robocath.
- The deal requires clearance from the French Ministry of Economy, introducing geopolitical/regulatory risk.
- Potential for significant dilution through the issuance of common stock and 'pre-funded' warrants.
📋 Key Facts
- Upfront consideration of $20.0 million payable in cash, stock (valued at $2.00 per share), or a combination.
- Contingent earnout payments of up to $25 million: $10 million for US FDA regulatory approval and $15 million for commercial sales milestones.
- Stereotaxis is providing interim financing to Robocath via bonds, with an initial expected amount of approximately €1.3 million.
- Closing is subject to a mandatory debt restructuring transaction by Stereotaxis and its lenders.
- The acquisition is expected to close in July 2026, with an 'end date' of December 31, 2026.
- Issuance of stock is subject to a 19.9% NYSE American Share Cap unless stockholder approval is obtained.
Stereotaxis, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2025. The filing serves as a formal notice of the earnings press release issued on March 9, 2026.
📋 Key Facts
- The report was filed on March 9, 2026, covering the period ending the same day.
- Financial results for the 2025 fourth quarter and full year were disclosed via an earnings press release.
- The information was filed under Item 2.02 (Results of Operations and Financial Condition).
- Exhibit 99.1 contains the detailed Earnings Press Release.
Stereotaxis, Inc. filed an 8-K to announce the release of its financial results for the third quarter of 2025. The filing serves as a formal notification that an earnings press release was issued on November 11, 2025.
📋 Key Facts
- Company reported Q3 2025 financial results on November 11, 2025.
- The filing includes an Earnings Press Release as Exhibit 99.1.
- Reported by Kimberly R. Peery, Chief Financial Officer.
Stereotaxis, Inc. entered into a sales agreement with Roth Capital Partners, LLC to facilitate the sale of up to $50,000,000 in common stock via an at-the-market (ATM) offering.
🚩 Red Flags
- Potential for significant shareholder dilution due to the $50M ATM offering.
- Use of proceeds includes 'working capital,' which often indicates a need to bolster cash runway in micro-cap companies.
📋 Key Facts
- Entered into a Sales Agreement with Roth Capital Partners, LLC on August 29, 2025.
- Aggregate sales price of up to $50,000,000 in common stock.
- Offering will be conducted via an 'at-the-market' (ATM) method or privately negotiated transactions.
- Roth Capital will receive a placement fee of up to 3.0% of gross sales.
- Proceeds are intended for working capital, R&D, and accelerating the commercialization pipeline.
Stereotaxis, Inc. filed an 8-K to announce the release of its financial results for the second quarter of 2025. The filing serves as a formal notice that the company's earnings press release is being made public.
📋 Key Facts
- Report date: August 7, 2025
- Reporting period: Second Quarter 2025
- The filing incorporates an Earnings Press Release as Exhibit 99.1
- Signed by Kimberly R. Peery, Chief Financial Officer
Stereotaxis, Inc. has entered into a registered direct offering to sell $12.5 million in common stock at a price of $2.00 per share. The offering is structured in two tranches: an initial closing expected on July 18, 2025, and an additional closing scheduled for November 25, 2025.
🚩 Red Flags
- Dilutive offering: Issuance of up to 6,250,000 new shares will dilute existing shareholders.
- Staged capital raise: The two-tranche structure suggests a need for continuous liquidity rather than a single lump sum.
📋 Key Facts
- Total offering size: $12.5 million in common stock at $2.00 per share.
- Initial Closing (expected July 18, 2025): 4,250,000 shares for $8.5 million gross proceeds.
- Additional Closing (scheduled November 25, 2025): 2,000,000 shares for $4.0 million gross proceeds.
- Placement Agent: Lake Street Capital Markets, LLC.
- Use of proceeds: Working capital, product commercialization, R&D, and general corporate purposes.
- Fees: 5.5% cash fee on the first $7.5 million of initial gross proceeds; no fees on the remaining $1.0M (initial) or $4.0M (additional).
Stereotaxis, Inc. issued a preliminary earnings release for the second quarter of 2025, forecasting significant year-over-year revenue growth.
🚩 Red Flags
- None identified in this preliminary earnings update.
📋 Key Facts
- Expected Q2 2025 revenue: $8.5 million to $8.8 million.
- Revenue growth expected to be ~15% sequentially vs Q1 2025.
- Revenue growth expected to be ~90% year-over-year vs Q2 2024.
- Gross margins for system and recurring revenue are expected to remain stable or slightly improve over Q1 2025 levels.
- GAAP operating expenses projected between $8.2 million and $8.8 million.
Stereotaxis, Inc. reported the results of its Annual Meeting of Shareholders held on May 15, 2025. The meeting resulted in the election of two Class III directors and the ratification of Ernst & Young LLP as the company's independent auditor for fiscal year 2025.
📋 Key Facts
- Annual Meeting held on May 15, 2025.
- Quorum was achieved with 63,792,419 shares represented (59% of outstanding voting shares).
- Dr. Nathan Fischel and Mr. Ross B. Levin were elected to the Board as Class III directors through May 2028.
- Proposal to ratify Ernst & Young LLP as independent registered public accounting firm for FY2025 was approved with 63,627,003 votes in favor.
Stereotaxis, Inc. filed an 8-K to announce the release of its financial results for the first quarter of 2025. The filing serves as a formal notification that earnings data is being made public via an accompanying press release.
📋 Key Facts
- The company issued an Earnings Press Release on May 12, 2025.
- The report covers financial results for the first quarter of 2025 (Q1 2025).
- The filing includes Exhibit 99.1 containing the full earnings press release.
Stereotaxis, Inc. filed an 8-K to announce its financial results for the fourth quarter and full fiscal year of 2024. The filing serves as a placeholder to incorporate the earnings press release into the company's official SEC record.
📋 Key Facts
- Report date: March 3, 2025
- Reporting period: Q4 and Full Year 2024
- The filing incorporates an Earnings Press Release as Exhibit 99.1
- Signed by Kimberly R. Peery, Chief Financial Officer
Stereotaxis, Inc. filed an 8-K to announce the release of its financial results for the third quarter of 2024. The filing serves as a formal mechanism to incorporate the company's earnings press release into its SEC reporting.
📋 Key Facts
- The company issued an Earnings Press Release on November 11, 2024.
- The report pertains to the financial results for the third quarter of 2024.
- The filing includes Exhibit 99.1 containing the full earnings press release.
Stereotaxis, Inc. filed an 8-K to announce the release of its financial results for the second quarter of 2024. The filing serves as a formal notice that an earnings press release has been issued.
📋 Key Facts
- The company reported its financial results for the second quarter of 2024 on August 12, 2024.
- The primary content is contained in Exhibit 99.1 (Earnings Press Release).
- The filing was signed by Kimberly R. Peery, Chief Financial Officer.
Stereotaxis, Inc. completed the acquisition of Access Point Technologies EP, Inc. (APT) on July 31, 2024. The transaction was settled primarily through the issuance of common stock.
🚩 Red Flags
- Issuance of restricted securities via private offering (Section 4(a)(2) and Rule 506).
📋 Key Facts
- Completed acquisition of all capital stock of Access Point Technologies EP, Inc. (APT).
- Transaction closed on July 31, 2024.
- Consideration included the issuance of 1,486,620 shares of Stereotaxis common stock.
- The acquisition was conducted pursuant to a Share Purchase Agreement dated May 11, 2024.
Stereotaxis, Inc. announced the election of Nachum “Homi” Shamir to its Board of Directors on July 18, 2024. The filing includes standard disclosures regarding director compensation and potential related-party transactions.
📋 Key Facts
- Nachum “Homi” Shamir was elected to the Board of Directors on July 18, 2024.
- Mr. Shamir will receive compensation consistent with other non-management Directors.
- The Company reported no material transactions involving Mr. Shamir exceeding $120,000 since January 1, 2024.
Stereotaxis, Inc. entered into a definitive agreement to acquire Access Point Technologies EP, Inc. (APT), a manufacturer of diagnostic catheters used in cardiac ablation procedures. The transaction is structured primarily as an all-stock deal with significant earnout provisions based on revenue and regulatory milestones.
🚩 Red Flags
- Significant potential dilution: The company anticipates filing a resale registration statement for approximately 6.1 million shares, which represents a substantial portion of the equity being used for the acquisition.
- Contingent liabilities: The earnout structure involves complex performance targets (revenue and regulatory) that could lead to significant future share issuances through 2029.
📋 Key Facts
- Acquisition of APT's equity interests to expand catheter portfolio for cardiac ablation.
- Consideration includes upfront Stereotaxis common stock and additional contingent stock via earnouts.
- Estimated 6.1 million shares of STXS to be registered for the transaction (upfront + milestones).
- Earnout period extends through the end of the calendar quarter following the fifth anniversary of closing.
- Closing is expected in Q3 2024, subject to customary conditions and APT shareholder approval.
- APT shareholders holding ~60% of voting power have entered into a Voting and Support Agreement.
- Termination fee of $1.0 million payable by APT if certain breach occurs.
Stereotaxis, Inc. announced its Q1 2024 financial results and simultaneously disclosed a definitive agreement to acquire Access Point Technologies EP, Inc., a developer of electrophysiology catheters.
🚩 Red Flags
- Multiple 8-K items in a single filing (Item 2.02 and Item 8.01) can sometimes indicate significant shifts or complex corporate actions occurring simultaneously.
📋 Key Facts
- Company released Q1 2024 financial results on May 13, 2024.
- Entered into a definitive share purchase agreement to acquire Access Point Technologies EP, Inc. (APT).
- The target company, APT, is a privately held Minnesota-based developer of electrophysiology catheters.
Stereotaxis, Inc. filed an 8-K to announce the release of its financial results for the fourth quarter and full fiscal year 2023.
📋 Key Facts
- The filing was made on March 4, 2024.
- The report pertains to Item 2.02 (Results of Operations and Financial Condition).
- Financial results for Q4 and Full Year 2023 were released via a press release (Exhibit 99.1).